ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1797

Wnt Signaling Pathway Status, Determined by Serum Dkk-1 and R-Spondin 1 Levels, in Rheumatoid Arthritis and Ankylosing Spondylitis

Byoong Yong Choi1, Hyon Joung Cho1, Eun Ha Kang2, Yeong Wook Song3 and Yun Jong Lee1, 1Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 2Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Dickkopf-1 (Dkk-1), known as inhibitor of Wnt signaling pathway, is involved in joint damage in inflammatory arthritis. While R-spondin 1 (Rspo1) reported to protect against bone destruction through antagonizing Dkk-1 in murine arthritis model, the Rspo1 levels in inflammatory arthropathy such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) has not been investigated. We determined the circulating levels of Rspo1 and Dkk-1 in patients with RA or AS and investigated their clinical implication.

Methods:

Serum sample were collected from 60 RA patients (mean age±SEM 53.3± 1.55, 54 females), 55 AS patients (36.7± 1.61, 8 females), and age-and gender-matched 65 healthy subjects (44.7±1.80, 35 females). Sera from 13 RA patients treated with anti-TNF-α agents were also collected at baseline and 12 weeks. Clinical and laboratory data included age, gender, body mass index, disease duration, medication history, ESR and CRP. Disease activities in RA and AS were measured by DAS28 or BASDAI respectively. Radiographic joint damages in RA were assessed by the modified Sharp/Van der Heijde score (Sharp score). Serum Rspo1 and Dkk-1 levels were determined by sandwich ELISA.

Results:

Serum Rspo1 levels were significantly decreased in RA patients when compared to those in healthy subjects (p<0.0001). However, their levels were comparable between AS patients and healthy subjects. While serum Dkk-1 levels in AS patients were significantly lower than those in healthy subjects (p=0.001), those in RA were significantly higher (p<0.0001). Thus, the ratios of Dkk-1/Rspo1 were significantly elevated in RA patients but significantly suppressed in AS patients (both p<0.0001). Dkk-1/Rspo1 ratios in RA patients with high disease activities (DAS28 > 5.1) were much higher than those in RA patients with low disease activities (DAS28 < 2.6, p=0.012). However, Dkk-1/Rspo1 ratios were not correlated with Sharp scores in RA patients and not different between AS patients with and without syndesmophyte. Serum DKK-1 levels wre not changed but Dkk-1/Rspo 1 ratios were decreased by anti-TNF-α treatment (p=0.0134). Glucocorticoid treatment (p=0.003) or presence of osteoporosis (p=0.044) was associated with increased Dkk-1/Rspo-1 ratios.

Conclusion:

This study demonstrated inappropriate suppression of Wnt signaling pathway, presented by high Dkk-1/Rspo1 ratios, in RA and activation of Wnt signaling pathway in AS. However, the ratios of Dkk-1/Rspo1 levels were not directly associated with the cumulative radiographic change in RA patients although their levels were affected by RA disease activity.


Disclosure:

B. Y. Choi,
None;

H. J. Cho,
None;

E. H. Kang,
None;

Y. W. Song,
None;

Y. J. Lee,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wnt-signaling-pathway-status-determined-by-serum-dkk-1-and-r-spondin-1-levels-in-rheumatoid-arthritis-and-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology